Actively Recruiting
Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer
Led by Jiuda Zhao · Updated on 2025-12-15
388
Participants Needed
1
Research Sites
149 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to elucidate the therapeutic efficacy of electroacupuncture in managing chemotherapy-induced gastrointestinal symptom clusters through clinical research. Building upon this foundation, multi-omics analyses will be conducted to investigate the regulatory effects and underlying mechanisms of electroacupuncture on gastrointestinal symptoms. Ultimately, genomic studies will be performed to further clarify the key targets of electroacupuncture intervention, thereby providing high-level evidence-based medical support and theoretical foundations for optimizing electroacupuncture strategies in addressing chemotherapy-induced gastrointestinal symptoms in patients with cancer.
CONDITIONS
Official Title
Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathologically confirmed stage I-III breast cancer
- ECOG Performance Status score of 0-1
- Age between 18 and 75 years
- Scheduled for highly emetogenic chemotherapy regimens (e.g., epirubicin + cyclophosphamide or platinum-based) during first cycle
- No acupuncture treatment within 1 month prior to enrollment
- Voluntary participation with written informed consent
- Expected survival of at least 3 months
- Premenopausal women agree to use contraception during study
- Adequate bone marrow, liver, and kidney function based on lab tests
You will not qualify if you...
- Advanced-stage cancer
- Receiving concurrent chemoradiotherapy
- Severe organ dysfunction preventing standard-dose chemotherapy
- Contraindications to acupuncture (e.g., active skin infections)
- Digestive diseases causing nausea/vomiting that interfere with assessment
- History of dry mouth (xerostomia)
- Known allergies to study drugs
- Pregnant or breastfeeding
- Using medications with antiemetic activity (except physiological doses or nighttime sedation)
- Seizure disorders requiring anticonvulsants
- Receiving thiazides as chronic antipsychotic therapy
- Known arrhythmias, uncontrolled heart failure, or recent heart attack
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Qinghai University Affiliated Hospital
Xining, Qinghai, China, 810000
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here